UPDATED: Pfizer gene therapy ups levels of dystrophin expression in Duchenne trial but another safety setback mars results – Endpoints News

After beefing up its pipeline last year with an in-licensing deal from Novartis, San Diego-based Amplyx has lined up an extension of their C round, designed to pay their way through a slate of mid-stage trials putting their experimental drugs to the test in humans. And this time theyre getting some bucks from Pfizer to pay for the next leg in the development process.

The new money a $53 million add to the first tranche in 2017 brings their C round total to $90 million-plus, with Pfizer joining a syndicate that includes Sofinnova Venture Partners, with participation from existing investors including New Enterprise Associates, Lundbeckfonden Ventures, Arix Bioscience, Pappas Capital, RiverVest Venture Partners, 35 Partners and BioMed Ventures. Adage Capital was another new investor in the round, with Pfizer, which brings the biotechs total raise to date to $140 million.

Read More

Continue reading here:

UPDATED: Pfizer gene therapy ups levels of dystrophin expression in Duchenne trial but another safety setback mars results - Endpoints News

Related Post

Comments are closed.